GLP1R and Werner syndrome: The anti-diabetic drug GLP-1R agonist liraglutide (LIR) and the anti-epileptic drug valproate (VPA) have shown promising results in preclinical studies and are assessed in upcoming clinical trials against WS progression (https://thesnowfoundation.org/clinical-trials/, accessed on 7 April 2021, ClinicalTrials.gov Identifier: NCT03717909 [54]).